Sacituzumab Govitecan Prolongs PFS in TNBCSacituzumab Govitecan Prolongs PFS in TNBC
Sacituzumab Govitecan Combo Reduces Progression, Death By 35% in Metastatic TNBC
| Read More |
FDA Accepts NDA for Bezuclastinib Combo in Gastrointestinal Stromal Tumors
| Read More |
New Career Center Video:
Learn how to build and strengthen your oncology referral network with expert insights from Tarita Thomas, MD, PhD, MBA, FACRO. Watch Increasing Your Oncology Referral Network now.
| Watch Here! |
Videos
 How AI is Redefining Diagnostic Imaging and Acquisition
|
 Prognostic Factors in EGFR-Mutant mNSCLC and Marathon Approach
|
Trending
 How Can Bioimpedance Spectroscopy Help Detect Lymphedema Quicker?
|
 Decoding the Top Moments in Prostate Cancer From 2025
|